title: Irbesartan: a review of its use in hypertension and diabetic nephropathy.
abstract: Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension. It is also approved in some regions for the treatment of nephropathy in patients with hypertension and type 2 diabetes mellitus. In adults with essential hypertension, irbesartan is effective at reducing blood pressure (BP) over a 24-hour period with once-daily administration. Irbesartan also slows the progression of renal disease in hypertensive patients with type 2 diabetes, with this effect partly independent of its BP-lowering effect. In addition, irbesartan was generally well tolerated in clinical trials. Thus, irbesartan is a useful treatment option for patients with hypertension, including those with type 2 diabetes and nephropathy.
authors.affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand.
authors.forename: Katherine F
authors.initials: KF
authors.lastname: Croom
authors.forename: Greg L
authors.initials: GL
authors.lastname: Plosker
mesh_terms: D000328:Adult; D047228:Angiotensin II Type 1 Receptor Blockers / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003928:Diabetic Nephropathies / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D000077405:Irbesartan; D013777:Tetrazoles / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000077405:Irbesartan